Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Hepatitis B virus

ABSTRACT: Ultra-deep sequencing of hepatitis B virus quasispecies in association with clinical status and nucleos(t)ide analogue treatment

PROVIDER: PRJDB2174 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	DRR001331.fastq.gz	Fastqsanger.gz
	DRR001332.fastq.gz	Fastqsanger.gz
	DRR001333.fastq.gz	Fastqsanger.gz
	DRR001334.fastq.gz	Fastqsanger.gz
	DRR001335.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 26

Shared Molecules

Only show the datasets with similarity scores above: 0.5

Threshold

0.5

Similar Datasets

Hepatitis C virus subtype 1b

Project description:Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing

| PRJDB1886 | ENA

Hepatitis B virus

Project description:Hepatitis B X gene 5' end at different clinical stages: comparing conservation/variability and quasispecies complexity

| PRJNA437055 | ENA

miRNA expression signatures in chronic hepatitis B (CHB) treated with nucleos(t)ide analogues (NA)

Project description:Hepatitis B virus (HBV) infection is one of the major causes of hepatocellular carcinoma (HCC). Nucleos(t)ide analogue (NA) therapy is effective to reduce the HCC incidence, while it doesn’t completely prevent HCC. In this study, we explored the involvement of microRNA (miRNA) in the post-NA treatment HCC development. Chronic hepatitis B (CHB) patients who received NA treatment (n = 18) were divided into 2 groups: those who didn’t develop HCC during the follow-up period (non-HCC group) and those who developed HCC after treatment (HCC group). Liver specimens were obtained before and after NA therapy, and HCC tissues were also obtained from the HCC group patients. Normal liver tissues were also obtained from 4 liver hemangioma patients who underwent surgical resection. miRNA expression was analyzed using Agilent miRNA microarray V3.

2018-09-23 | GSE110217 | GEO

Hepatitis B virus

Project description:Kinetics of Hepatitis B surface antigen (HBsAg) quasispecies during REP2139-Ca therapy in HBeAg+ chronic HBV infection

| PRJNA478149 | ENA

Hepatitis B virus

Project description:The complex patterns of quasispecies in the reverse transcriptase region of hepatitis B virus in Telbivudine treatment

| PRJNA335918 | ENA

Rimonabant suppresses RNA transcription of hepatitis B virus by inhibiting HNF4α

Project description:The emergence of drug-resistant viruses against nucleot(s)ide analogs (NAs), which are the main treatment for chronic hepatitis B virus (HBV) infection, has become a problem. To discover novel anti-HBV compounds with a low risk of emergence of drug-resistant viruses, we performed screening of a G protein-coupled receptor-associated compound library and identified Rimonabant as a candidate. Transcriptome analysis of Rimonabant-treated primary hepatocytes by RNA sequencing revealed that the transcriptional activity of HNF4α, which is known to stimulate viral RNA synthesis, was depressed.

2020-01-26 | GSE139597 | GEO

Hepatitis B virus

Project description:Analysis of Ultra-deep Pyrosequencing and Cloning Based Sequencing of the Basic Core Promoter/Precore/Core Region of Hepatitis B Virus Using Newly Developed Bioinformatics Tools

| PRJNA239442 | ENA

Hepatitis B virus

Project description:COMPLEX GENOTYPE MIXTURES ANALYZED BY DEEP SEQUENCING IN TWO DIFFERENT REGIONS OF HEPATITIS B VIRUS GENOME

| PRJNA291355 | ENA

Hepatitis B virus

Project description:Hepatitis B virus Epigenomics

| PRJNA377217 | ENA

Hepatitis B virus

Project description:Hepatitis B virus Genome sequencing

| PRJNA944979 | ENA